Published: Vol 8, Iss 24, Dec 20, 2018 DOI: 10.21769/BioProtoc.3116 Views: 5656
Reviewed by: Vamseedhar RayaproluPaul JordanAnonymous reviewer(s)
Protocol Collections
Comprehensive collections of detailed, peer-reviewed protocols focusing on specific topics
Related protocols
Measurement of the Activity of Wildtype and Disease-Causing ALPK1 Mutants in Transfected Cells With a 96-Well Format NF-κB/AP-1 Reporter Assay
Tom Snelling
Nov 20, 2024 807 Views
Quantitative Measurement of the Kinase Activity of Wildtype ALPK1 and Disease-Causing ALPK1 Mutants Using Cell-Free Radiometric Phosphorylation Assays
Tom Snelling
Nov 20, 2024 756 Views
Fluorescence Polarization-Based High-Throughput Screening Assay for Inhibitors Targeting Cathepsin L
Keyu Guo [...] Shuyi Si
Jul 20, 2025 865 Views
Abstract
Complement pathways function to identify and remove pathogens and infected cells. There are three complement pathways: the classical, lectin and alternative pathway (AP). While all pathways are activated following pathogen stimuli, the AP is constitutively active and tightly controlled by activators (e.g., Factor B, Factor D) and negative regulators (e.g., Factor H). Complement activity can be measured by well-established methods that are often used in a diagnostic setting to determine the CH50 (50% complement hemolytic activity) or AP50, specifically to measure AP activity. The protocol here has adapted the traditional AP50 method designed to measure AP activity in human sera, to measure the positive or negative AP regulatory activity within a given test sample. The assay relies on the ability of AP components in human serum to lyse rabbit erythrocytes under in vitro conditions specific for the AP with subsequent release of hemoglobin that is quantitated by measurement of optical density. Our method has added test substances, such as cell culture media with defined changes in individual complement components and determined the ability to either promote or inhibit AP activity in vitro. Thus, this protocol reflects the overall functional ability of a sample to effect AP activity and can be used in the research laboratory to determine AP regulatory activity in a complex biological sample, or to test the ability of drugs or novel biomolecules to regulate AP activity.
Keywords: ComplementBackground
Complement is part of the innate immune system and acts to recognize and clear pathogens and stimulate adaptive immune responses. The three complement pathways, the classical (CP), lectin (LP) and alternative pathways (AP), constitute a series of cleavage and activation of complement proteins, generating enzymatically active protein complexes, such as convertase complexes, and bioactive split products, such as C3a. The three pathways converge on cleavage of the complement component C3 and one common downstream outcome is the generation of a membrane attack complex (MAC) and subsequent lysis of target cells (Ricklin et al., 2010). Functional activity of complement can be measured by assays such as the 50% complement hemolytic activity (CH50 assay), where a stimulus (antibody coated red blood cells), is provided in vitro to the complement components in a biological sample. The subsequent lysis of the target red blood cells (RBC) is quantitated by release of hemoglobin and measured by an increase in optical density. If target complement components such as C3 are missing from the test biological sample, either genetically or due to complement consumption resulting from activation of complement in vivo, then CH50 will be low. Similarly, the AP50, specifically measures the activity of the AP where rabbit RBC spontaneously activate the human AP resulting in RBC lysis (Figure 1A). The presence of EGTA chelates calcium to prevent CP activation and the addition of Mg2+, restores this requirement for the AP, yielding buffer conditions specific to determine AP activity (Joiner et al., 1983). CH50 and AP50 assays are routinely used in many diagnostic laboratories to quantitate complement activity in human blood (Prohaszka et al., 2016). In the traditional application of the AP50, a high AP activity is reflected by low availability of complement components due to complement ‘consumption’ and thus low lysis of rabbit RBC. The lysis of rabbit RBC is quantitated by detecting the release of free hemoglobin by an increase in optical density (Figure 1A). This traditional assay has been adapted here, to keep the starting complement components in the assay constant by use of one source of human serum and measure the ability of factors added in test substances to promote the cleavage of the complement components from human serum, under conditions specific for the AP (Figure 1B). In this case, with constant input of complement components, adding a sample containing a stimulator, such as factor D or B will result in increased RBC lysis, while adding a negative regulator, such as factor H (FH) will result in decreased RBC lysis. A previous study has applied a similar approach to measure complement convertase activity in human serum (Blom et al., 2014) and the method here has adapted this to measure the net stimulatory or inhibitory ability of cell culture supernatants for the AP (Cabezas et al., 2018).
Figure 1. Comparison of traditional (A) and adapted (B) AP activity assays. Method (A) uses variable levels of HuS to quantitate AP activity in the test HuS samples. Our adapted method (B) utilizes a constant HuS sample and quantitates the AP regulatory activity of added test samples. HuS = human serum; OD = optical density.
Materials and Reagents
Equipment
Procedure
Data analysis
Recipes
Final con. | For 1 L |
0.01 M EGTA | 3.80 g |
0.1% (w/v) gelatin | 200 ml 2% gelatin solution |
Final con. | For 1 L |
0.15 M NaCl | 8.76 g |
Final con. | For 1 L |
10 N | 400 g |
Note: All buffers are made up in MilliQ water.
Acknowledgments
Ms Cabezas-Falcon is supported by an Australian International Post-graduate Research Scholarship.
Competing interests
Authors have no conflicts of interest or competing interests.
Ethics
Human sera was collected in accordance with approval from the Southern Adelaide Clinical Human Research Ethics Committee (SA HREC EC00188), ORF number 343.16. Sheep blood was collected in accordance with the Flinders University Animal Welfare Committee approval to use scavenge material.
References
Article Information
Copyright
© 2018 The Authors; exclusive licensee Bio-protocol LLC.
How to cite
Falcon, S. C., Gordon, D. L. and Carr, J. M. (2018). Quantitation of Regulatory Activity for the Complement Alternative Pathway Using an Adaptation of the AP50 in vitro Assay. Bio-protocol 8(24): e3116. DOI: 10.21769/BioProtoc.3116.
Category
Immunology > Complement analysis > Virus
Microbiology > Microbe-host interactions > Virus
Biochemistry > Protein > Activity
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.
Share
Bluesky
X
Copy link